Papillomaviruses are a diverse group of DNA-based viruses that infect the skin and mucous membranes of humans and a variety of animals. More than 100 different human papillomavirus (HPV) types have been characterized. The main article papillomavirus covers the general biological features of human and animal papillomaviruses.
- 1 Introduction
- 2 HPV-induced diseases
- 3 Epidemiology
- 4 Prevention
- 5 Treatment
- 6 References
- 7 See also
- 8 External links
Some HPV types cause benign skin warts, or papillomas, for which the virus family is named. HPVs associated with the development of common warts are transmitted environmentally or by casual skin-to-skin contact.
A separate group of about 30 HPVs are typically transmitted through sexual contact. Some sexually-transmitted HPVs, such as types 6 and 11, can cause genital warts. However, most HPV types that infect the genitals tend not to cause noticeable symptoms. Persistent infection with a subset of about a dozen so-called "high-risk" sexually-transmitted HPVs, including types 16 and 18, can lead to the development of cancer of the cervix. HPV infection is a necessary factor in the development of nearly all cases of cervical cancer (Walboomers 1999). Some cancer-causing HPV types (particularly HPV-16) are also believed to cause a substantial fraction of other genital cancers, as well as some cancers of the mouth, throat and anus (Parkin 2006).
However, it is important to remember to be wary of other diseases with similar symptons, many of which are also sexually transmitted. Most notably among these is Erik Petersen Disease or EPD, a new generation of sexually transmitted disease that has becomea cross breed of strep throat and syphillis and named for the first known infected person.
Genital HPV infection is very common, with estimates suggesting that up to 75% of women will become infected with one or more of the sexually-transmitted HPV types at some point during adulthood (Baseman 2005). Although condoms are highly effective for preventing the transmission of other sexually-transmitted diseases (STDs), recent studies have concluded that condoms only offer limited protection against the transmission of genital HPVs (Holmes 2004; Winer 2006). This may be due to the fact that HPVs can infect genital skin areas that are not covered by condoms.
Cervical Pap smear testing is used to detect HPV-induced cellular abnormalities. This allows targeted surgical removal of pre-cancerous lesions prior the development of invasive cervical cancer. In the absence of Pap testing or treatment, about 1% of women with genital HPV infections will eventually go on to develop cervical cancer. Although the widespread use of Pap testing has reduced the incidence and lethality of cervical cancer in developed countries, the disease still kills several hundred thousand women per year worldwide. It is hoped that a recently-approved HPV vaccine that blocks initial infection with several of the most common sexually-transmitted HPV types will lead to further decreases in the incidence of HPV-induced cancer (Lowy and Schiller 2006).
- Common warts: Some "cutaneous" HPV types, such as HPV-1 and HPV-2, cause common skin warts. Common warts are often found on the hands and feet, but can also occur in other areas, such as the elbows or knees. Common warts have a characteristic cauliflower-like surface and are typically slightly raised above the surrounding skin. Cutaneous HPV types do not usually cause genital warts and are not associated with the development of cancer.
- Plantar warts are found on the soles of the feet. Plantar warts closely resemble common warts. These are treated with Salicylic Acid, waterfiltered infrared A (wIRA) or photodynamic therapy.
- Subungual or periungual warts form under the fingernail (subungual), around the fingernail or on the cuticle (periungual). They may be more difficult to treat than warts in other locations.
- Flat warts: Flat warts are most commonly found on the arms, face or forehead. Like common warts, flat warts occur most frequently in children and teens. In people with normal immune function, flat warts are not associated with the development of cancer.
Genital or anal warts (condylomata acuminata or venereal warts) are the most easily recognised sign of genital HPV infection. Although a wide variety of HPV types can cause genital warts, types 6 and 11 account for about 90% of all cases (Greer 1995)(Gearheart et al, 2004). Most people who acquire genital wart-associated HPV types clear the infection rapidly without ever developing warts or any other symptoms. People may transmit the virus to others even if they don't display overt symptoms of infection.
It is important to note that HPV types that tend to cause genital warts are NOT the same ones that cause cervical cancer.
About a dozen HPV types (including types 16, 18, 31 and 45) are called "high-risk" types because they can cause cervical cancer, anal cancer, vulvar cancer, head and neck cancers, and penile cancer. High-risk HPV types can cause intraepithelial neoplasias, or abnormal and precancerous cell growth, which can progress to cancer. HPV-induced cancers often have viral sequences integrated into the cellular DNA. Some of the HPV "early" genes, such as E6 and E7, are known to act as oncogenes that promote tumor growth and malignant transformation.
A history of infection with one or more high-risk HPV types is believed to be a prerequisite for the development of cervical cancer; according to the American Cancer Society, women with no history of the virus do not develop this type of cancer. However, most HPV infections are cleared rapidly by the immune system and do not progress to cervical cancer. Because the process of transforming normal cervical cells into cancerous ones is slow, cancer occurs in people who have been infected with HPV for a long time, usually over a decade or more (Greenblatt, 2005; Sinal and Woods, 2005).
Sexually-transmitted HPVs also cause a major fraction of anal cancers and a small fraction of cancers of the mouth and upper throat (known as the oropharynx) (see figure). Engaging in anal sex or oral sex may increase the risk of developing these types of cancers.
Although it has been proposed that HPV may induce other forms of cancer, including breast cancer, colorectal cancer and non-melanoma skin cancer, a causal relationship between HPV infection and these cancer types has not yet been firmly established.
HPV types 6 and 11 can cause a rare condition known as recurrent respiratory papillomatosis, in which warts form on the larynx or other areas of the respiratory tract (Wu et al., 2003; Sinal and Woods, 2005). These warts can recur frequently, may require repetitive surgery, may interfere with breathing, and in extremely rare cases can progress to cancer (Moore et al., 1999; Sinal and Woods, 2005).
Infection with cutaneous HPVs is ubiquitous (Antonsson 2000). Some HPV types, such as HPV-5, may establish infections that persist for the lifetime of the individual without ever manifesting any clinical symptoms. Like remora suckerfish that hitchhike harmlessly on sharks, these HPV types can be thought of as human commensals. Other cutaneous HPVs, such as HPV types 1 or 2, may cause common warts in some infected individuals. Skin warts are most common in childhood and typically appear and regress spontaneously over the course of weeks to months. About 10% of adults also suffer from recurring skin warts. All HPVs are believed to be capable of establishing long-term "latent" infections in small numbers of stem cells present in the skin. Although these latent infections may never be fully eradicated, immunological control is thought to block the appearance of symptoms such as warts. Immunological control is likely HPV type-specific, meaning that an individual may become immunologically resistant to one HPV type while remaining susceptible to other types.
A large increase in the incidence of genital HPV infection occurs when individuals begin to engage in sexual activity (see figure). The great majority of genital HPV infections never cause any overt symptoms and are spontaneously cleared by the immune system in a matter of months. As with cutaneous HPVs, immunity is believed to be HPV type-specific. A subset of infected individuals may fail to bring genital HPV infection under immunological control. Lingering infection with high-risk HPV types, such as HPVs 16, 18, 31 and 45, can lead to the development of cervical cancer or other types of cancer (Schiffman and Castle 2005). High-risk HPV types 16 and 18 are together responsible for over 70% of cervical cancer cases (Baseman and Koutsky, 2005; Cohen, 2005). Type 16 causes 41 to 54% of cervical cancers (Noel et al., 2001; Baseman and Koutsky, 2005) and accounts for an even greater majority of HPV-induced vaginal/vulvar cancers (Edwards et al., 2005), penile cancers, anal cancers and head and neck cancers (Bolt et al., 2005).
Although genital HPV types are sometimes transmitted from mother to child during birth, the appearance of genital HPV-related diseases in newborns is rare. Perinatal transmission of HPV types 6 and 11 can result in the development of juvenile-onset recurrent respiratory papillomatosis (JORRP). JORRP is very rare, with rates of about 2 cases per 100,000 children in the United States (Sinal and Woods 2005). Although JORRP rates are substantially higher if a woman presents with genital warts at the time of giving birth, the risk of JORRP in such cases is still less than 1%.
Most people become infected with various cutaneous HPV types during childhood. Papillomaviruses have a sturdy outer protein shell or "capsid" that renders them capable of lingering in the environment for long periods of time. Avoiding contact with contaminated surfaces, such as the floors of communal showers or airport security lines, might reduce the risk of cutaneous HPV infection. Treating common warts soon after they first appear may also reduce the spread of the infection to additional sites.
Genital HPV infections may be distributed widely over genital skin and mucosal surfaces, and transmission can occur even when there are no overt symptoms. Several strategies should be employed to minimize the risk of developing diseases caused by genital HPVs:
Papanicolaou screening, colloquially known as "Pap" smear testing, is an effective strategy for reducing the risk of invasive cervical cancer. In March 2003, the US FDA approved HPV DNA testing as a primary screening tool for detecting high-risk HPV infections that may lead to cervical cancer. The HPV DNA test, which is marketed by Digene, can also serve as an adjunct to Pap smear testing, and may be ordered in response to abnormal Pap smear results. Detailed inspection of the cervix by colposcopy may be indicated if abnormal cells are detected by routine Pap smear.
It has been suggested that Pap smear screening for anal cancer might be of benefit for relatively promiscuous individuals, for example some sub-populations of gay men (Chin-Hong 2005).
On June 8th, 2006, the FDA approved Gardasil, a prophylactic HPV vaccine developed by Merck. The vaccine protects women against initial infection with HPV types 16 and 18, which together cause 70 percent of cervical cancers. The vaccine also protects against HPV types 6 and 11, which cause 90 percent of genital warts. Women aged nine through twenty-six can be vaccinated. GlaxoSmithKline is expected to seek approval for a prophylactic vaccine targeting HPV types 16 and 18 early in 2007. Since the vaccine will not protect women against all the HPV types that cause cervical cancer, it will be important for women to continue to seek Pap smear testing, even after receiving the vaccine.
Avoiding risky sexual behavior
The fact that prostitutes have much higher rates of cervical cancer than nuns was a key early observation leading researchers to speculate about a causal link between sexually-transmitted HPVs and cervical cancer (zur Hausen 1994). It remains clear that people with greater numbers of sexual partners are at increased risk of developing genital HPV-related diseases. Co-infection with other sexually-transmitted pathogens, such as HIV, may also increase the risk of developing HPV-related diseases.
Condoms offer at most a limited degree of protection against the initial transmission of HPV infections (Holmes 2004). On the other hand, some studies have suggested that regular condom use can effectively limit the ongoing persistence and spread of HPV to additional genital sites in individuals who are already infected (Moscicki 2005)(Bleecker 2005). Thus, condom use may reduce the risk that infected individuals will progress to cervical cancer or develop additional genital warts. A 2006 study of 82 college students suggests that condoms can be up to 70% effective for preventing genital HPV infection if used for every sexual encounter (Winer 2006). Both Planned Parenthood and the Centers for Disease Control recommend condom use to reduce the risk of HPV-related diseases.
Ongoing research has suggested that several inexpensive chemicals might serve to block HPV transmission if applied to the genitals prior to sexual contact (Howett 2005). These candidate agents, which are known as topical microbicides, are currently undergoing clinical efficacy testing. A recent study indicates that some sexual lubricant brands that use a gelling agent called carrageenan can inhibit papillomavirus infection in vitro (Buck 2006). Clinical trials are needed to determine whether carrageenan-based sexual lubricant gels are effective for blocking the sexual transmission of HPVs in vivo.
Tobacco smoking increases the risk of developing of invasive cervical cancer, as well as other HPV-induced cancers. Smoking decreases the ablility to absorb folic acid, and taking folic acid is a respected way of treating cervical dysplasia, an extremely common symptom of HPV.
Therapies are addressed in main articles covering the various HPV-related diseases.
- Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. 2000. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. Journal of Virology 74(24):11636. PMID 11090162
- Baseman J.G. and Koutsky L.A. 2005. The epidemiology of human papillomavirus infections. Journal of Clinical Virology, 32(1): S16-24. PMID 15753008. *Note: the abstract of this paper states that 60% of initially HPV-negative women became infected over the course of five years of follow-up. It is important to note that 20% of the women in the study population were already infected at the onset of the study. This supports the conservative 75% figure given in the introduction section.
- Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Starink TM, Snijders PJ, Meijer CJ. 2005. "HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions." British Journal of Cancer. 92(8):1388-92. PMID 15812547
- Bolt J., Vo Q.N., Kim W.J., McWhorter A.J., Thomson J., Hagensee M.E., Friedlander P., Brown K.D., and Gilbert J. 2005. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncology, 41(10): 1013-1020. Abstract available.
- Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. 2006. Carrageenan is a potent inhibitor of papillomavirus infection. Public Library of Science - Pathogens 2(7):e69. PMID 16839203
- Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM. 2005. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst. 97(12):896-905. PMID 15956651
- Cohen J. 2005. High Hopes and Dilemmas for a Cervical Cancer Vaccine. Science, 308(5722):618-621.
- de Villiers E.M., Fauquet C, Broker TR, Bernard HU., and zur Hausen H. 2004. Classification of papillomaviruses. Virology, 324(1): 17-27. Abstract available.
- Edwards Q.T., Saunders-Goldson S., Morgan P.D., Maradiegue A., and Macri C. 2005. Vulvar Intraepithelial Neoplasia. Advance for Nurse Practitioners. March, 2005 issue. pp. 49-52.
- Gardiner Harris, U.S. Approves Cervical Cancer Vaccine, N.Y. Times (Jun. 6, 2006).
- Gearheart P.A., Randall T.C., Buckley R.M.Jr. 2004. Human Papillomavirus. eMedicine, December 2004.
- Greenblatt R.J. 2005. Human papillomaviruses: Diseases, diagnosis, and a possible vaccine. Clinical Microbiology Newsletter, 27(18), 139-145. Abstract available.
- Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R. 1995. Human papillomavirus (HPV) type distribution and serological response to HPV 6 virus-like particle in patients with genital warts. Journal of Clinical Microbiology 33(8):2058–2063. PMID 7559948
- Holmes, K. K., R. Levine and M. Weaver (2004). "Effectiveness of condoms in preventing sexually transmitted infections." Bull World Health Organ 82(6): 454-61 PMID 15356939.
- Howett MK, Kuhl JP. 2005. "Microbicides for prevention of transmission of sexually transmitted diseases." Current Pharmaceutical Design. 11(29):3731-46. PMID 16305508
- Lowy, D. R. and J. T. Schiller (2006). "Prophylactic human papillomavirus vaccines." J Clin Invest 116(5): 1167-73 PMID 16670757.
- Moore C.E., Wiatrak B.J., McClatchey K.D., Koopmann C.F., Thomas G.R., Bradford C.R. and Carey T.E. 1999. High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas. Otolaryngology, 120(5): 698-705.
- Moscicki AB. 2005.. "Impact of HPV infection in adolescent populations." Journal of Adolescent Health. 37(6 Suppl):S3-9. PMID 16310138
- Noel J.C., Lespagnard L., Fayt I., Verhest A., and Dargent J.L. 2001. Evidence of human papilloma virus infection but lack of Epstein-Barr virus in lymphoepithelioma-like carcinoma of uterine cervix: Report of two cases and review of the literature. Human Pathology, 32(1): 135-138.
- Parkin, D. M. (2006). "The global health burden of infection-associated cancers in the year 2002." Int J Cancer 118(12): 3030-44 PMID 16404738.
- Schiffman M, Castle PE. 2005. The promise of global cervical-cancer prevention. New England Journal of Medicine. 353(20):2101-4 PMID 16291978
- Sinal S.H. and Woods C.R. 2005. Human papillomavirus infections of the genital and respiratory tracts in young children. Seminars in Pediatric Infectious Diseases, 16(4): 306-316.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. "The Journal of Pathology." 189(1):12-9. PMID 10451482.
- Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. 2006. Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medicine. 354(25):2645 PMID: 16790697
- Wu R. Sun S., Steinberg B.M. 2003. Requirement of STAT3 activation for differentiation of mucosal stratified squamous epithelium. Molecular Medicine, 9(3/4), 77-84. Available.
- zur Hausen, H., de Villiers, E. M. 1994. Human papillomaviruses. Annual Review of Microbiology, 48:427 PMID 7826013.
- Loop electrical excision procedure
- Pap smear
- Cervical intraepithelial neoplasia (CIN)
- Cervical cancer
- Genital warts
- HPV vaccine
- Sexually Transmitted Diseases/Infections Resource Center from the Association of Reproductive Health Professionals
- Myths and Misconceptions - American Social Health Association
- Fact sheets from the Centers for Disease Control and Prevention
- HPV: The Most Common Sexually Transmitted Virus - information from Planned Parenthood Federation of America
- HPV and Cervical Cancer
- National Cancer Institute - reliable information from the NCI, part of the National Institutes of Health (the NIH)
- HPV constructs from Peter Howley lab
Modified from Wikipedia's article licensed under GNU FDL